Janssen Pharmaceutica Nv

Ortho-Mcneil Pharmaceutical Corp.

Janssen Biotech, Inc.

Protagonist Therapeutics, Inc.

Leonard, Kristi a.

Anne Fourie

Xiaohua Xue

David A Kummer

Ronald L Wolin

Hariharan Venkatesan

Rachel T Nishimura

Aihua Wang

Maud J Urbanski

Craig R Woods

James Patrick Edwards

Kevin Douglas Kreutter

Kristi A Leonard

Steven D Goldberg

Umar Maharoof

Kent Barbay

Maxwell David Cummings

Virginia M Tanis

Christian Gege

Christoph Steeneck

Olaf Kinzel

Gerald Kleymann

Thomas Hoffmann

Connor L Martin

Elizabeth G Fennema

William Moore Jones

Lars Karlsson

Cheryl A Grice

Laurent Gomez

Ashok Bhandari

John J M Wiener

Christa C Chrovian

Santhosh Francis Neelamkavil

Kelly J McClure

Wendy Eccles

Genesis M Bacani

Robin L Thurmond

Alejandro Santillán, Jr

Alice Lee-Dutra

Hong Mimi Zhou

Aaron M Kearney

Xiaoli Cheng

Carl L Manthey

Adrienne M Landry-Bayle

Taraneh Mirzadegan

Paul H Kim

David C Polidori

Joan M Pierce

Ryan Eberwine

Kelly Ganamet

Fawn Coles

Geraldine Broeckx

Dajun Sun

Giustino Di Pretoro

Gopal Rajan

Nathalie Mertens

Shu Li

Felix Lai

Mohammad Masjedizadeh

Beverly Knight

Nishit Modi

Kelly Lynn Ganamet

Kelly Mcclure

Joan Pierce

The present invention relates to compositions of peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salt or solvate forms thereof, corresponding pharmaceutical compositions, methods and/or uses for treatment of autoimmune inflammation and related diseases and disorders.

Compositions of peptide inhibitors of Interleukin-23 receptor

Anti-HLA-C6 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as autoimmune diseases.

Anti-HLA-C antibodies and uses thereof

The present invention comprises compounds of Formula I. wherein:R, R, R, R, R, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-&#x3b3;-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR&#x3b3;t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Pyridinyl pyrazoles as modulators of ROR&#x3b3;T

The present invention comprises compounds of Formula I. wherein:R, Q, R, R, R, R, A, and Aare defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-&#x3b3;-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR&#x3b3;t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

6-aminopyridin-3-yl pyrazoles as modulators of RORgT

The present invention comprises compounds of Formula I. wherein:R, R, R, R, R, R, R, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-&#x3b3;-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR&#x3b3;t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Phenyl substituted pyrazoles as modulators of ROR&#x3b3;t

The present invention comprises compounds of Formula I. wherein:R, R, R, R, R, R, R, R, and Rare defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR&#x3b3;t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim

Alkyl linked quinolinyl modulators of ROR&#x3b3;t

Phenyl linked quinolinyl modulators of ROR&#x3b3;t

The present invention comprises compounds of Formula I. wherein: The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR&#x3b3;t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim

Quinolinyl modulators of ROR&#x3b3;t

The present invention comprises compounds of Formula I wherein:R, R, R, R, R, R, R, and {circle around (A)} are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR&#x3b3;t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Thiazoles as modulators of ROR&#x3b3;t

The present invention comprises compounds of Formula I. wherein:X, A, A, A, A, R, R, and Rare defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR&#x3b3;t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim

Trifluoromethyl alcohols as modulators of ROR&#x3b3;t

The present invention comprises compounds of Formula I. wherein:R, R, R, R, A, A, and are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR&#x3b3;t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Amide substituted thiazoles as modulators of RORyt

Heteroaryl linked quinolinyl modulators of ROR&#x3b3;t

Methylene linked quinolinyl modulators of ROR&#x3b3;t

Growing community of inventors

San Diego, CA, United States of America

Anne Fourie